CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial

Oct 04, 2024 8:30am EDT

CytoDyn Announces Preliminary Findings in Study with SMC Laboratories

Sep 24, 2024 8:30am EDT

September 2024 Letter to Shareholders

Sep 09, 2024 8:30am EDT

CytoDyn Engages Leading CRO For Phase II Inflammation Trial

Aug 23, 2024 8:30am EDT

CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer

Aug 12, 2024 8:30am EDT

CytoDyn Announces Settlement with Amarex Clinical Research LLC

Jul 09, 2024 8:30am EDT

CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024

Jun 27, 2024 8:30am EDT

CytoDyn to Host Webcast to Provide Company Update

May 28, 2024 8:30am EDT

May 2024 Letter to Shareholders

May 16, 2024 8:30am EDT

CytoDyn Announces FDA Has Lifted Clinical Hold

Feb 29, 2024 8:30am EST